US 12,280,147 B2
PEG lipidoid compounds
Shrirang Karve, Lexington, MA (US); Yi Zhang, Lexington, MA (US); Frank DeRosa, Lexington, MA (US); and Michael Heartlein, Lexington, MA (US)
Assigned to TRANSLATE BIO, INC., Waltham, MA (US)
Appl. No. 17/291,919
Filed by Translate Bio, Inc., Lexington, MA (US)
PCT Filed Nov. 7, 2019, PCT No. PCT/US2019/060339
§ 371(c)(1), (2) Date May 6, 2021,
PCT Pub. No. WO2020/097379, PCT Pub. Date May 14, 2020.
Claims priority of provisional application 62/758,084, filed on Nov. 9, 2018.
Prior Publication US 2022/0071905 A1, Mar. 10, 2022
Int. Cl. A61K 9/127 (2006.01); A61K 9/1273 (2025.01); A61K 38/17 (2006.01); A61K 38/45 (2006.01); C08G 65/48 (2006.01)
CPC A61K 9/1273 (2013.01) [A61K 38/1709 (2013.01); A61K 38/45 (2013.01); C08G 65/48 (2013.01)] 21 Claims
 
1. A polymer, comprising:
(i) a polyethylene glycol (PEG) moiety having a first and a second end, and
(ii) two or more lipid substructures, wherein each lipid substructure independently comprises a ceramide lipid, a glycerolipid, a sterol, a phospholipid, or alkylated citric acid;
wherein the first and second ends of the PEG moiety are each covalently attached to at least one of the two or more lipid substructures.